Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the third leading cause of cancer deaths, and while mortality has largely improved in the developed world, five-year survival for metastatic disease remains dismally low at only 15%. Fortunately, nearly a dozen targeted therapies and immunotherapies have been FDA approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Rawla, Prashanth, Barsouk, Adam, Hadjinicolaou, Andreas V., Barsouk, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723550/
https://www.ncbi.nlm.nih.gov/pubmed/31366129
http://dx.doi.org/10.3390/medsci7080083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723550/
https://www.ncbi.nlm.nih.gov/pubmed/31366129
http://dx.doi.org/10.3390/medsci7080083

Ejemplares similares